A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Mitotech, SA91 enrolled

Overview

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

Single-center, double-masked, randomized, placebo-controlled study comprising 4 visits over the course of approximately 5 weeks. The study included a 1-week placebo (SkQ1 vehicle) run-in period between Visit 1 and Visit 2, and approximately 28 days of twice daily (BID) dosing (Visit 2 - Visit 4). Qualified subjects were randomized 1:1:1 to receive either 1.55 µg/mL SkQ1 ophthalmic solution, 0.155 µg/mL SkQ1 ophthalmic solution, or placebo (vehicle of SkQ1 ophthalmic solution). The following primary endpoints were tested: * Corneal Fluorescein staining in the inferior region Pre-CAE at Visit 4 (Day 29), as measured by the Ora Calibra Scale in the worst eye at baseline; * Worst dry eye symptom (ocular discomfort, dryness, or grittiness - as determined from subject diary data recorded during the 1-week run-in period between Visit 1 and Visit 2) evaluated over the seven days preceding Visit 4 (not including day of visit) during the treatment period.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Keratoconjunctivitis Sicca

Interventions

Low Dose 0.155µg/mL SkQ1 ophthalmic solutionDRUG

eyedrops

High Dose 1.55µg/mL SkQ1 ophthalmic solutionDRUG

eyedrops

Placebo (Vehicle) opthalmic solutionDRUG

eyedrops

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Be male or female of any race, at least 18 years of age * Have provided written informed consent * Have a reported history of dry eye syndrome * Have a history of use or desire to use eye drops for dry eye Exclusion Criteria: * Have any clinically significant eye findings that require therapeutic treatment or may interfere with study parameters * Have previously had LASIK surgery within the last 12 months * Have used Restasis® within 30 days of Visit 1 * Be a woman who is pregnant, nursing or planning a pregnancy * Be unwilling to submit a urine pregnancy test if of childbearing potential * Have a known allergy and/or sensitivity to the test article or its components, including the preservative benzalkonium chloride * Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1 * Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Locations (1)

Lawrence General Hospital

Andover, Massachusetts, United States

Outcomes

Primary Outcomes

Inferior Corneal Fluorescein Staining

The dry eye sign primary efficacy variable of corneal fluorescein staining of the inferior region of the eye measured on a 0-4 point scale where 0 = no staining and 4 = most staining between treatment arms at day 29

Time frame: Day 29

Worst Symptom Based on Diary Data

Worst dry eye symptom (as determined from subject diary data recorded during the 1-week run-in period) evaluated over the seven days preceding Day 29 during the treatment period. The scale was on a 0-5 range where 0= no symptoms and 5= worst symptoms measured for a number of dry eye symptoms.

Time frame: Day 29

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.